Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, boosted by an endorsement from President Trump, filed for emergency authorization for its Covid-19 drug therapy, while Gilead Sciences inked European supply deal. The post Covid Report: Regeneron Pharmaceuticals Files For Emergency Authorization; Gilead Inks European Supply Deal appeared first on Investor's Business Daily.

Covid Report: Regeneron Pharmaceuticals Files For Emergency Authorization; Gilead Inks European Supply Deal

After the U.S. bought almost all of the global supply of the antiviral drug, many European countries reported shortages amid a surge in coronavirus cases

EU Secures Up To 500,000 Remdesivir Treatment Courses Amid Global Shortages

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) and the European Commission today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU). The JPA enables participating countries in the EU and the European Economic Area (EEA) and the UK to purchase Veklury for both real-time demand and stockpiling needs, coordinate

Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Pfizer

West Pharmaceutical Services

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on InvestorPlace.

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

White House doctors' choice of their therapies to treat President Trump for Covid-19 boosted Regeneron and Gilead shares Monday; an analyst expects FDA approval of Regeneron treatment soon. The post Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President appeared first on Investor's Business Daily.

Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President

Kraft Heinz

Got $5,000? These 2 Dividend Stocks Are Cheap Buys Today

Broadcom

Altria

Southern Company

AT&T

New month... new stock considerations. I can't believe that October is already here... the final quarter of 2020. Seeing how fast time blows by simply reminds me to stay invested no matter how crazy the market seems to be.

October 2020 Stock Considerations

Amgen

Our indicative theme on Covid-19 Treatment Stocks is up 13% this year, compared to the 4% gain for the S&P 500. While anti-viral therapeutics are quite complex to develop, companies have largely been adapting existing therapies for Covid treatments while also developing new treatment options.

Gilead, Regeneron, Amgen: Covid Treatment Stocks Still Worth Looking At As Vaccine Nears?

Pinterest

Conagra Brands

Crocs

Constellation Brands

Pinterest, Crocs, Gilead Sciences, Constellation Brands and ConAgra Foods were our top stock trades from Thursday. The post 5 Top Stock Trades for Friday: PINS, CROX, STZ, CAG, GILD appeared first on InvestorPlace.

5 Top Stock Trades for Friday: PINS, CROX, STZ, CAG, GILD

Shares of Gilead Sciences Inc. GILD, 0.41% were down 0.3% in trading on Thursday after the drugmaker announced it is now in charge of distributing remdesivir, its COVID-19 treatment, as of Oct. 1.

Gilead takes over remdesivir distribution in the U.S.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Since the COVID-19 pandemic began, Gilead has worked diligently to ramp up production and rapidly expand the supply of our investigational antiviral drug Veklury® (remdesivir) by making significant investments to increase internal manufacturing capacity, expand our contract manufacturing network and implement process improvements. While working to increase our manufacturing capacity over these past months, the company also donated 1.5 million vials of Veklu

Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States

AstraZeneca

Johnson & Johnson

Moderna

5 Vaccine Stocks to Buy Now

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the HIV Glasgow 2020 conference, taking place virtually from October 5-8. Gilead will present 13 studies from the company’s HIV research and development programs in addition to supporting several other independent studies at the conference, which, along with its community-focused programs, reflect Gilead’s ongoing focus and commitment to advancing scientific discovery and sup

Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020

Immunomedics

Some investors are questioning whether the $21 billion Gilead Sciences Inc. (NASDAQ:GILD) agreed to pay for Immunomedics Inc. (NASDAQ:IMMU) last week was too much.

Did Gilead Pay Too Much for Immunomedics?

These big biotechs are both moving into new areas. Which is most likely to move the needle for investors?

Better Buy: Gilead Sciences vs. Amgen

Galapagos

Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.

Gilead & Galapagos' RA Drug Receives Approval in Europe

Anheuser-Busch InBev

Canadian National Railway Company

Goldman Sachs

Stryker

Chicago, IL – September 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman Sachs

FOSTER CITY, Calif., & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rhe

European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Despite a 25% decline in Gilead Sciences stock since late April this year, at the current price of just over $60, we believe GILD stock has more downside. Why is that?

Gilead Stock’s Down To $60, But It Hasn’t Hit A Bottom Yet

Credit markets have more than fully recovered since the March crunch and M&A activity has picked up noticeably.

High Probability M&A Situation After Gilead Wins Bidding War

Alexion Pharma

Biogen

Vertex Pharmaceuticals

The short interest data are out for September 15, the most recent settlement date.

Biotech Short Sellers Hike Their Bets

Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.

Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan

Both biotechs could be winners in fighting COVID-19, but which is more likely to be the bigger winner for investors?

Better Coronavirus Stock: Gilead Sciences vs. Moderna

Gilead Sciences: Debt Fueled Bottom

FOSTER CITY, Calif. & TOKYO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the preve

News for Gilead Sciences Stock (GILD)